Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 ☒ 

QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period September 30, 2017ended March 31, 2023

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 ☐ 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________to________________________to____________

 

Commission file number000-22904

 

PARKERVISION, INC.

(Exact name of registrant as specified in its charter)

 

Florida

59-2971472

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No)

incorporation or organization)

 

7915 Baymeadows Way,4446-1A Hendricks Avenue, Suite 400354

Jacksonville, Florida 32256 32207

(Address of principal executive offices)

 

(904) 732-6100

(Registrant’s telephone number, including area code)

 

N/A

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol

Name of Each Exchange on Which Registered

None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes☒   No.

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such file). Yes ☒   No ☐ .

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.  (Check one):Act:

 

Large accelerated filer  ☐

Accelerated filer  ☐

Non-accelerated filer    ☐(Do not check if a smaller reporting company)

Smaller reporting company  ☒

Emerging growth company ☐

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐   No

 

As of NovemberMay 10, 2017, 19,695,9792023, 85,176,496 shares of the issuer’s common stock, $.01 par value, were outstanding.

 


 


TABLE OF CONTENTS

 

PART I - FINANCIAL INFORMATION

Item 1.    Condensed Consolidated Financial Statements (Unaudited)

2

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

15

19

Item 3. Quantitative and Qualitative Disclosures About Market Risk

21

23

Item 4. Controls and Procedures

21

23

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

22

24

Item 1A. Risk Factors

22

24

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

23

24

Item 3. Defaults Upon Senior Securities

23

24

Item 4. Mine Safety Disclosures

23

24

Item 5. Other Information

24

Item 6. Exhibits

24

25

SIGNATURES

25

26

EXHIBIT INDEX

26

 

1

 

1


PARTPART I - FINANCIAL INFORMATION

 

ITEMITEM 1. Condensed Consolidated Financial Statements (Unaudited)

 

PARKERVISION, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

(in thousands, except par value data)

 


 

 

 

 

 

 

 

 

September 30,

 

December 31,

2017

 

2016

 

March 31, 2023

  

December 31, 2022

 

CURRENT ASSETS:

 

 

 

 

 

 

Cash and cash equivalents

$

283 

 

$

258  $135  $109 

Restricted cash equivalents

 

153 

 

911 

Available-for-sale securities

 

101 

 

14 

Inventories

 

1,128 

 

170 

Prepaid expenses and other

 

1,249 

 

 

686 

Restricted cash

 13,925  - 

Prepaid expenses

 226  244 

Other current assets

  24   30 

Total current assets

 

2,914 

 

 

2,039  14,310  383 

 

 

 

 

 

PROPERTY AND EQUIPMENT, net

 

397 

 

269 

 

 

 

 

INTANGIBLE ASSETS, net

 

5,360 

 

6,268 

 

 

 

 

OTHER ASSETS, net

 

15 

 

 

 -

Intangible assets, net

 1,252  1,359 

Operating lease right-of-use assets

 3  4 

Other assets, net

  4   5 

Total assets

$

8,686 

 

$

8,576  $15,569  $1,751 

 

 

 

 

 

 

CURRENT LIABILITIES:

 

 

 

 

 

Accounts payable

$

770 

 

$

595  $810  $901 

Accrued expenses:

 

 

 

 

 

Salaries and wages

 

316 

 

297  47  23 

Professional fees

 

676 

 

455  29  79 

Other accrued expenses

 

211 

 

267  501  486 

Notes payable, current portion

 

825 

 

825 

Deferred rent, current portion

 

15 

 

51 

Deferred revenue

 

19 

 

 

19 

Related party note payable, current portion

 130  139 

Convertible notes, current portion

 1,375  625 

Operating lease liabilities

  3   4 

Total current liabilities

 

2,832 

 

 

2,509  2,895  2,257 

 

 

 

 

 

LONG-TERM LIABILITIES:

 

 

 

 

 

Capital lease, net of current portion

 

 

 -

Deferred rent, net of current portion

 

40 

 

Secured contingent payment obligation

 

14,056 

 

 

14,185  38,903  40,708 

Unsecured contingent payment obligations

 6,545  5,089 

Convertible notes, net of current portion

 3,663 3,913 

Related party note payable, net of current portion

  440   473 

Total long-term liabilities

 

14,099 

 

 

14,186   49,551   50,183 

Total liabilities

 

16,931 

 

 

16,695   52,446   52,440 

 

 

 

 

 

 

COMMITMENTS AND CONTINGENCIES

 

 

 

 

       

 

 

 

 

 

SHAREHOLDERS' (DEFICIT) EQUITY:

 

 

 

 

Common stock, $.01 par value, 30,000 shares authorized,

18,601 and 13,183 shares issued and outstanding

at September 30, 2017 and December 31, 2016, respectively

 

186 

 

132 

Accumulated other comprehensive income

 

 -

 

 -

Warrants outstanding

 

826 

 

826 

SHAREHOLDERS' DEFICIT:

 

Common stock, $0.01 par value, 175,000 shares authorized, 84,523 and 81,246 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively

 845  812 

Additional paid-in capital

 

355,823 

 

343,087  392,388  391,724 

Accumulated deficit

 

(365,080)

 

 

(352,164)  (430,110)  (443,225)

Total shareholders' (deficit) equity

 

(8,245)

 

 

(8,119)

Total liabilities and shareholders' (deficit) equity

$

8,686 

 

$

8,576 

 

 

 

 

 

Total shareholders' deficit

  (36,877)  (50,689)

Total liabilities and shareholders' deficit

 $15,569  $1,751 


 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

2


 

PARKERVISION, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSSINCOME

(UNAUDITED)

 (in(in thousands, except per share data)

 




 

 

 

 

 

 

 

 

 

 

 



 

 

 

 

 

 

 

 

 

 

 



Three Months Ended

 

Nine Months Ended



September 30,

 

September 30,



2017

 

2016

 

2017

 

2016

Revenue

$

 -

 

$

4,000 

 

$

 -

 

$

4,064 

Cost of sales

 

 -

 

 

(301)

 

 

 -

 

 

(342)

Gross margin

 

 -

 

 

3,699 

 

 

 -

 

 

3,722 



 

 

 

 

 

 

 

 

 

 

 

Research and development expenses

 

911 

 

 

1,016 

 

 

3,538 

 

 

2,380 

Selling, general and administrative expenses

 

3,423 

 

 

3,620 

 

 

9,481 

 

 

13,453 

Total operating expenses

 

4,334 

 

 

4,636 

 

 

13,019 

 

 

15,833 



 

 

 

 

 

 

 

 

 

 

 

Interest and other income

 

 

 

 

 

26 

 

 

17 

Interest expense

 

(16)

 

 

(16)

 

 

(52)

 

 

(51)

(Loss) gain on changes in fair value

 

(38)

 

 

(726)

 

 

129 

 

 

(3,033)

Total interest and other

 

(46)

 

 

(737)

 

 

103 

 

 

(3,067)



 

 

 

 

 

 

 

 

 

 

 

Net loss before income taxes

 

(4,380)

 

 

(1,674)

 

 

(12,916)

 

 

(15,178)



 

 

 

 

 

 

 

 

 

 

 

Foreign income tax expense

 

 -

 

 

(660)

 

 

 -

 

 

(660)



 

 

 

 

 

 

 

 

 

 

 

Net loss

 

(4,380)

 

 

(2,334)

 

 

(12,916)

 

 

(15,838)



 

 

 

 

 

 

 

 

 

 

 

Other comprehensive (loss) gain, net of tax:

 

 

 

 

 

 

 

 

 

 

 

Unrealized (loss) gain on available-for-sale securities

 

(4)

 

 

(2)

 

 

 -

 

 

(1)

Other comprehensive (loss) gain, net of tax

 

(4)

 

 

(2)

 

 

 -

 

 

(1)



 

 

 

 

 

 

 

 

 

 

 

Comprehensive loss

$

(4,384)

 

$

(2,336)

 

$

(12,916)

 

$

(15,839)



 

 

 

 

 

 

 

 

 

 

 

Basic and diluted net loss per common share

$

(0.24)

 

$

(0.18)

 

$

(0.76)

 

$

(1.33)



 

 

 

 

 

 

 

 

 

 

 

Weighted average common shares outstanding

 

18,026 

 

 

12,846 

 

 

16,923 

 

 

11,949 



 

 

 

 

 

 

 

 

 

 

 

  

Three Months Ended March 31,

 
  

2023

  

2022

 

Revenue

 $25,000  $- 

Cost of sales

  (43)  (3)

Gross margin

  24,957   (3)
         

Selling, general and administrative expenses

  12,085   1,933 

Total operating expenses

  12,085   1,933 
         

Other income

  -   28 

Interest expense

  (106)  (62)

Change in fair value of contingent payment obligations

  349   2,302 

Total interest and other

  243   2,268 
         

Provision for income taxes

  -   - 
         

Net income

  13,115   332 
         

Other comprehensive income, net of tax

  -   - 
         

Comprehensive income

 $13,115  $332 
         

Earnings per common share

        

Basic

 $0.16  $0.00 

Diluted

 $0.11  $0.00 
         

Weighted average common shares outstanding

        

Basic

  83,968   77,553 

Diluted

  121,696   106,472 


 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

PARKERVISION, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWSSHAREHOLDERS’ DEFICIT

(UNAUDITED)

(in thousands)

 




 

 

 

 

 

 

 

 

 

 

 



 

 

 

 

 

 

 

 

 

 

 



Three Months Ended

 

Nine Months Ended



September 30,

 

September 30,



2017

 

2016

 

2017

 

2016

CASH FLOWS FROM OPERATING ACTIVITIES:

 

 

 

 

 

 

 

 

 

 

 

Net loss

$

(4,380)

 

$

(2,334)

 

$

(12,916)

 

$

(15,838)

Adjustments to reconcile net loss to net cash used in operating
   activities:

 

 

 

 

 

 

 

 

 

 

 

Depreciation and amortization

 

321 

 

 

343 

 

 

972 

 

 

997 

Share-based compensation

 

503 

 

 

1,423 

 

 

1,708 

 

 

1,488 

Loss on disposal of assets

 

 -

 

 

 -

 

 

71 

 

 

Realized gain on available-for-sale securities

 

(5)

 

 

 -

 

 

(9)

 

 

(1)

Loss (gain) on changes in fair value

 

38 

 

 

726 

 

 

(129)

 

 

3,033 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

 

 

 

Inventories

 

(828)

 

 

 -

 

 

(958)

 

 

 -

Prepaid expenses and other assets

 

473 

 

 

(131)

 

 

(153)

 

 

(229)

Accounts payable and accrued expenses

 

666 

 

 

(2,895)

 

 

357 

 

 

(1,196)

Deferred rent

 

38 

 

 

(18)

 

 

 

 

(55)

Deferred revenue

 

 -

 

 

(1)

 

 

 -

 

 

(2)

Total adjustments

 

1,206 

 

 

(553)

 

 

1,862 

 

 

4,036 

Net cash used in operating activities

 

(3,174)

 

 

(2,887)

 

 

(11,054)

 

 

(11,802)



 

 

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM INVESTING ACTIVITIES:

 

 

 

 

 

 

 

 

 

 

 

Purchase of available-for-sale investments

 

(2)

 

 

(2,402)

 

 

(4,813)

 

 

(4,404)

Proceeds from redemption of available-for-sale securities

 

1,935 

 

 

1,975 

 

 

4,735 

 

 

5,565 

Payments for patent costs and other intangible assets

 

(14)

 

 

(7)

 

 

(40)

 

 

(113)

Purchases of property and equipment, net

 

(146)

 

 

(2)

 

 

(217)

 

 

(4)

Net cash provided by (used in) investing activities

 

1,773 

 

 

(436)

 

 

(335)

 

 

1,044 



 

 

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES:

 

 

 

 

 

 

 

 

 

 

 

Net proceeds from issuance of common stock and warrants in
   public and private offerings

 

1,019 

 

 

2,861 

 

 

10,769 

 

 

3,810 

Net proceeds from exercise of options and warrants

 

 -

 

 

422 

 

 

 -

 

 

422 

Principal payments on capital lease obligation

 

 -

 

 

 -

 

 

(1)

 

 

(51)

Proceeds from contingent payment obligation

 

 -

 

 

 -

 

 

 -

 

 

13,000 

Repayment of contingent payment obligation

 

 -

 

 

(3,340)

 

 

 -

 

 

(3,340)

Shares withheld for payment of taxes

 

(34)

 

 

(57)

 

 

(112)

 

 

(57)

Net cash provided by (used in) financing activities

 

985 

 

 

(114)

 

 

10,656 

 

 

13,784 



 

 

 

 

 

 

 

 

 

 

 

NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH EQUIVALENTS

 

(416)

 

 

(3,437)

 

 

(733)

 

 

3,026 



 

 

 

 

 

 

 

 

 

 

 

CASH, CASH EQUIVALENTS, AND RESTRICTED CASH EQUIVALENTS, beginning of period

 

852 

 

 

6,638 

 

 

1,169 

 

 

175 



 

 

 

 

 

 

 

 

 

 

 

CASH, CASH EQUIVALENTS, AND RESTRICTED CASH EQUIVALENTS, end of period

$

436 

 

$

3,201 

 

$

436 

 

$

3,201 



 

 

 

 

 

 

 

 

 

 

 

  

Three Months Ended March 31,

 
  

2023

  

2022

 

Total shareholders' deficit, beginning balances

 $(50,689) $(44,777)
         

Common stock

        

Beginning balances

  812   770 

Issuance of common stock and warrants in private offerings, net of issuance costs

  8   - 

Issuance of common stock upon exercise of options and warrants

  1   5 

Issuance of common stock, warrants, and options for services

  2   - 

Issuance of common stock upon conversion and payment of interest-in-kind on convertible debt

  20   3 

Share-based compensation, net of shares withheld for taxes

  2   - 

Ending balances

  845   778 
         

Additional paid-in capital

        

Beginning balances

  391,724   387,865 

Issuance of common stock and warrants in private offerings, net of issuance costs

  127   (18)

Issuance of common stock upon exercise of options and warrants

  3   77 

Issuance of common stock, warrants, and options for services

  79   - 

Issuance of common stock upon conversion and payment of interest-in-kind on convertible debt

  270   79 

Share-based compensation, net of shares withheld for taxes

  185   746 

Ending balances

  392,388   388,749 
         

Accumulated deficit

        

Beginning balances

  (443,225)  (433,412)

Comprehensive income for the period

  13,115   332 

Ending balances

  (430,110)  (433,080)
         

Total shareholders' deficit, ending balances

 $(36,877) $(43,553)


 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

PARKERVISION, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

(in thousands)


  

Three Months Ended March 31,

 
  

2023

  

2022

 

CASH FLOWS FROM OPERATING ACTIVITIES:

        

Net income

 $13,115  $332 

Adjustments to reconcile net income to net cash provided by (used in) operating activities:

        

Depreciation and amortization

  66   83 

Share-based compensation

  187   746 

Gain on changes in fair value of contingent payment obligations

  (349)  (2,302)

Loss on disposal/impairment of equipment and intangible assets

  43   8 

Changes in operating assets and liabilities:

        

Prepaid expenses and other assets

  105   110 

Accounts payable and accrued expenses

  (12)  191 

Operating lease liabilities

  (1)  (40)

Total adjustments

  39   (1,204)

Net cash provided by (used in) operating activities

  13,154   (872)
         

CASH FLOWS FROM INVESTING ACTIVITIES:

        

Purchases of property and equipment

  -   - 

Net cash used in investing activities

  -   - 
         

CASH FLOWS FROM FINANCING ACTIVITIES:

        

Net proceeds (payments) from issuance of common stock in private offerings

  135   (18)

Net proceeds from exercise of options and warrants

  4   82 

Net proceeds from debt financings

  700   - 

Principal payments on long-term debt

  (42)  (24)

Net cash provided by financing activities

  797   40 
         

NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH

  13,951   (832)
         

CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period

  109   1,030 
         

CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of period

 $14,060  $198 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

PARKERVISION, INC.

CONDENSED NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

 

1. Description of Business

 

ParkerVision, Inc. and its wholly-owned German subsidiary, ParkerVision GmbH (collectively “ParkerVision”, “we” or the “Company”), is in the business of innovating fundamental wireless hardware technologies and products.

We have designed and developed a consumer distributed Wi-Fi product line that is being marketed under the brand name Milo™.  We also design, develop and market our proprietary radio frequency (“RF”) technologies and integrated circuits based on those technologies, and we license those technologies to others for use in semiconductor circuits for wireless communication products, includingproducts.  We have expended significant financial and other resources to research and develop our own internally developed products.RF technologies and to obtain patent protection for those technologies in the United States of America (“U.S.”) and certain foreign jurisdictions.  We believe certain patents protecting our proprietary technologies have been broadly infringed by others, and therefore the primary focus of our business plan includesis the enforcement of our intellectual property rights through patent licensing and infringement litigation efforts.  We currently have patent enforcement actions ongoing in various U.S. district courts against mobile handset, smart television and licensing efforts.    other WiFi product providers, as well as semiconductor suppliers, for the infringement of a number of our RF patents.  We have made significant investments in developing and protecting our technologies.

 

2. Liquidity and Going Concern

 

Our accompanying condensed consolidated financial statements were prepared assuming we would continue as a going concern, which contemplates that we will continue in operation for the foreseeable future and will be able to realize assets and settle liabilities and commitments in the normal course of business.  These condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that could result should we be unable to continue as a going concern.

We have incurred significant losses from operations and negative cash flows in every year since inception and have utilized the proceeds from the sales of our equity securities and contingent funding arrangements with third-parties to fund our operations, including the cost of litigation.  For the ninethree months ended September 30, 2017,March 31, 2023, we incurred arecognized net lossincome of approximately $12.9$13.1 million and negative cash flows from operations of approximately $11.0$13.2 million.  At September 30, 2017,March 31, 2023, we had cash and cash equivalents, excluding restricted cash, of approximately $0.1 million and an accumulated deficit of approximately $365$430.1 million.  These circumstances raise substantial doubt aboutWe had restricted cash of approximately $13.9 million at March 31, 2023, all of which was used to make a repayment on our ability to continue to operate as a going concern within one year following the issue date of these condensed consolidated financial statements.secured contingent payment obligation in May 2023.   

 

At September 30, 2017,For the three months ended March 31, 2023, we had cash, cash equivalents,received aggregate net proceeds from debt and available-for-sale securitiesequity financings of approximately $0.4 million and restricted cash equivalents of approximately $0.2$0.8 million. We began shipments of our Milo Wi-Fi product line in October 2017.  Although we anticipate revenues and margin generated by this consumer product will begin to offset our operating costs in the fourth quarter of 2017, the revenues and margins generated in the short-term will not be sufficient to fully fund our operations without the need for additional working capital.

In August 2017, On May 4, 2023, we entered into an At-Market Issuance Sales Agreement (“ATM”)a confidential letter agreement with FBR Capital Markets & Co. for the sale ofBrickell whereby Brickell provided $5.0 million in new funding to us on substantially similar repayment terms as those set forth in our common stock having an aggregate offering price of upexisting contingent payment agreement, but at a lower interest rate.   These proceeds will be used to $4.4 million.support our operations.  We sold 0.64 million shares ofbelieve our common stock for net proceeds of approximately $1.0 million under this agreement as of September 30, 2017 and had approximately $3.2 million remaining available under the ATM which we intend to use to fund our short-term workingcurrent capital needs.

5


Our abilityresources are sufficient to meet our liquidity needs for at least the next twelve months is dependent upon (i) our ability to develop, market and sell existing and new products; (ii) our ability to successfully negotiate licensing agreements and/or settlements relating to the use of our technologies by others in excess of our contingent payment obligations; and/or (iii) our ability to obtain additional debt or equity financing.  We expect that revenue generated from product sales, patent enforcement actions, and technology licenses over the next twelve months may not be sufficient to cover our working capital requirements.   In the event we do not generate sufficient revenues to cover our operational costs and contingent repayment obligations, we willnot be required to use available working capital and/or raiseseek additional working capital through the sale of equity securities or other financing arrangements.capital.  

 

We expect to continue to invest in the support of our patent prosecutionlicensing and enforcement product development,program.  A significant amount of future proceeds that we may receive from our patent licensing and sales, marketing,enforcement program will be first utilized to repay borrowings and customer support forlegal fees and expenses under our technologies and products.contingent funding arrangements.  The long-term continuation of our business plan is dependent upon the generation of sufficient revenuescash flows from our technologies and/or products to offset expenses and contingent paymentdebt obligations.  In the event that we do not generate sufficient revenues,cash flows, we will be required to obtain additional funding through public or private debt or equity financing or contingent fee arrangements and/or reduce operating costs.  Failure to generate sufficient revenues,cash flows, raise additional capital through debt or equity financings or contingent fee arrangements, and/or reduce operating costs will have a material adverse effect on our ability to meet our long-term liquidity needs and achieve our intended long-term business objectives.

 

6

3. Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements for the period ended September 30, 2017March 31, 2023 were prepared in accordance with accounting principles generally accepted in the United States of Americaaccounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q10-Q and Rule 10-0110-01 of Regulation S-X.S-X.  Operating results for the three and nine months ended September 30, 2017March 31, 2023, are not necessarily indicative of the results that may be expected for the year ending December 31, 20172023, or future years.  Certain reclassifications have been made to prior period amounts to conform to the current period presentation.  All normal and recurring adjustments which, in the opinion of management, are necessary for a fair statement of the consolidated financial condition and results of operations have been included.

 

The year-end condensed consolidated balance sheet data was derived from audited financial statements for the year ended December 31, 2016, but does not include all2022.  Certain information and disclosures required by GAAP.normally included in the notes to the annual financial statements prepared in accordance with GAAP have been omitted from these interim condensed consolidated financial statements.  These interim condensed consolidated financial statements should be read in conjunction with our latest Annual Report on Form 10-K10-K for the year ended December 31, 2016.  2022 (“2022 Annual Report”).

 

The condensed consolidated financial statements include the accounts of ParkerVision, Inc. and its wholly-owned German subsidiary, ParkerVision GmbH, after elimination of all intercompany transactions and accounts.

 

4. Accounting Policies

 

There have been no changes in accounting policies from those stated in our 2022Annual Report on Form 10-K for the year ended December 31, 2016, except as follows:

Recent Accounting Pronouncements

In May 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting.  This update provides guidance on the types of changes to the terms or conditions of share-

6


based payment awards to which an entity would be required to apply modificationReport.  We do not expect any newly effective accounting under ASC 718. The new standard is effective for annual periods beginning after December 15, 2017 and interim periods within those years. Early adoption is permitted. The adoption of this guidance is not expectedstandards to have a material effectimpact on our consolidated financial statements.position, results of operations or cash flows when they become effective. 

5. Revenue

 

In February 2016, the FASB issued ASU 2016-02 “Leases,” to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements.    Under the new guidance, a lessee will be required to recognize assets and liabilities for capital and operating leases with lease terms of more than 12 months.  ASU 2016-02 is effective for interim and annual periods beginning after December 15, 2018.  Early adoption is permitted.  We are currently assessing the impact of this update on our consolidated financial statements. We have identified all existing operatingan active monitoring and financing leases and areenforcement program with respect to our intellectual property rights that includes seeking appropriate compensation from third parties that utilize or have utilized our intellectual property without a license.  As a result, we may receive payments as part of a settlement or in the processform of determining the present value of existing lease assets and liabilities under the new guidance.court-awarded damages for a patent infringement dispute.  We are also currently formalizing processes and controls to identify, classify and measure new leasesrecognize such payments as revenue in accordance with ASU 2016-02.  The impact of ASU 2016-02 on our consolidated financial statements is currently being evaluated.

In May 2014, the FASB issued ASU 2014-09,“RevenueAccounting Standards Codification (“ASC”) 606, “Revenue from Contracts with Customers.”  ASU 2014-09 implements a common revenue standard that clarifies the principles for recognizing revenue.  This new revenue recognition model provides a five-step analysis in determining when and how revenue is recognized.    ASU 2015-14, “Revenue from Contracts with Customers (Topic 606)”, issued in August 2015, defers adoption of ASU 2014-09 to annual reporting periods beginning after December 15, 2017.  Early adoption is not permitted.  We do not expect the adoption of ASU 2014-09 to have a material effect on our consolidated financial statements.

 

5.  LossWe recognized $25.0 million of revenue during the three-month period ended March 31, 2023 from patent license and settlement agreements with third parties for their use of our technologies.  Our performance obligations were satisfied, and therefore revenue recognized, upon transfer of the licensed rights and dismissal of all patent enforcement actions between the parties.  No revenue was recognized during the three months ended March 31, 2022

7

6. Earnings per Common Share

 

Basic lossearnings per common share is determined based on the weighted-average number of common shares outstanding during each period. 

The dilutive effect of outstanding options and warrants is calculated using the treasury stock method.  The dilutive effect of shares underlying convertible notes was calculated using the if-converted method.

The following table shows the computation of basic and diluted earnings per share for the three months ended March 31, 2023 and 2022 (net income and shares in thousands):


  

March 31,

 
  

2023

  

2022

 

Numerator

        

Net income

 $13,115  $332 

Effect of dilutive securities

  99   56 

Net income adjusted for dilutive effect

  13,214   388 
         

Denominator:

        

Weighted-average basic shares outstanding

  83,968   77,553 

Effect of dilutive securities

  37,728   28,919 

Weighted-average diluted shares

  121,696   106,472 
         

Basic earnings per share

 $0.16  $0.00 

Diluted earnings per share

 $0.11  $0.00 

Diluted lossearnings per common share isfor the same as basic loss per common share as allthree months ended March 31, 2023 and 2022 excludes options and warrants that are anti-dilutive.  The anti-dilutive common share equivalents are excluded from the calculation,at March 31, 2023 and 2022 were as their effect is anti-dilutive.follows (in thousands):


  

March 31,

 
  

2023

  

2022

 

Options outstanding

  17,526   13,413 

Warrants outstanding

  7,346   7,346 
   24,872   20,759 

8

7. Cash, Cash Equivalents and Restricted Cash

 

OptionsCash, cash equivalents and warrantsrestricted cash of $14.06 million as of March 31, 2023, consists of $0.135 million of cash and cash equivalents and $13.925 million in restricted cash.  Restricted cash represents cash held in escrow by our attorneys designated for repayment of principal on our secured contingent debt obligation.  These restricted funds were released from escrow and remitted to purchase approximately 1.4 million and 1.0 million shares of common stock were outstanding at September 30, 2017 and 2016, respectively.  In addition, unvested restricted stock units (“RSUs”), representing approximately 0.6 million and 0.3 shares of common stock were outstanding at September 30, 2017 and 2016, respectively.   These options, warrants and RSUs were excluded from the computation of diluted loss per common share as their effect would have been anti-dilutive.Brickell in May 2023.   

8. Prepaid Expenses

 

6.  Inventories

Inventories consistedPrepaid expenses consist of the following (in thousands):

 



 

 

 

 

 

 



 

 

 

 

 

 



 

September 30,

 

December 31,



 

2017

 

2016

Raw materials

 

$

958 

 

$

 -

Work-in-process

 

 

125 

 

 

126 

Finished goods

 

 

45 

 

 

44 

Total inventories

 

$

1,128 

 

$

170 



 

 

 

 

 

 

7


7.   Prepaid Expenses and Other

  

March 31, 2023

  

December 31, 2022

 

Prepaid services

 $185  $202 

Prepaid insurance

  24   25 

Prepaid licenses, software tools and support

  15   15 

Other prepaid expenses

  2   2 
  $226  $244 

 

Prepaid expensesservices at March 31, 2023 and other consistDecember 31, 2022 include approximately $0.2 million and $0.2 million, respectively of consulting services paid in shares of stock or warrants to purchase shares of stock in the following (in thousands): 

future.

 



 

 

 

 

 

 



 

September 30,

 

December 31,



 

2017

 

2016

Prepaid services

 

$

521 

 

$

448 

Prepaid licenses

 

 

300 

 

 

 -

Prepaid insurance

 

 

99 

 

 

108 

Prepaid inventory and production costs

 

 

93 

 

 

 -

Prepaid advertising and other

 

 

173 

 

 

70 

Short-term deposits and other current assets

 

 

63 

 

 

60 



 

$

1,249 

 

$

686 



 

 

 

 

 

 

8.9. Intangible Assets

 

Intangible assets consist of the following (in thousands):


  

March 31, 2023

  

December 31, 2022

 

Patents and copyrights

 $14,216  $14,319 

Accumulated amortization

  (12,964)  (12,960)
  $1,252  $1,359 

9

10. Debt

Related Party Note Payable

We have an unsecured promissory note of approximately $0.6 million payable to Sterne, Kessler, Goldstein, & Fox, PLLC (“SKGF”), a related party, for outstanding unpaid fees for legal services.  In 2022, SKGF agreed to amend the note in order to change and extend the final balloon payment due under the note from April 2023 to April 2027.  The SKGF note, as amended, will continue to accrue interest at a rate of 4% per annum, requires monthly payments of principal and interest of $12,500 with a final balloon payment of approximately $0.02 million in April 2027.  We are currently in compliance with all the terms of the note. 

Convertible Notes

Our convertible notes represent 5-year promissory notes that are convertible, at the holders’ option, into shares of our common stock at fixed conversion prices.  Interest payments are made on a quarterly basis and are payable, at our option, subject to certain equity conditions, in either cash, shares of our common stock, or a combination thereof.  The number of shares issued for interest is determined by dividing the interest payment amount by the closing price of our common stock on the trading day immediately prior to the scheduled interest payment date.  To date, all interest payments on the convertible notes have been made in shares of our common stock. We have recognized the convertible notes as debt in our condensed consolidated financial statements.

We have the option to prepay the majority of the notes, subject to a premium on the outstanding principal prepayment amount of 25% prior to the two-year anniversary of the note issuance date, 20% prior to the three-year anniversary of the note issuance date, 15% prior to the four-year anniversary of the note issuance date, or 10% thereafter.  The notes provide for events of default that include failure to pay principal or interest when due, breach of any of the representations, warranties, covenants or agreements made by us, events of liquidation or bankruptcy, and a change in control.  In the event of default, the interest rate increases to 12% per annum and the outstanding principal balance of the notes plus all accrued interest due may be declared immediately payable by the holders of a majority of the then outstanding principal balance of the notes.

For the three months ended March 31, 2023, convertible notes with a face value of $0.2 million were converted, at the option of the holder, into approximately 1.5 million shares of our common stock.  For the three months ended March 31, 2023, we recognized interest expense of approximately $0.1 million related to the contractual interest on our convertible notes which we elected to pay in shares of our common stock and issued approximately 428,000 shares of our common stock as interest-in-kind payments.

In January 2023, we issued 5-year convertible notes with an aggregate face value of $0.7 million to accredited investors.  The notes have a conversion price of $0.16 per share.  The shares underlying the notes, as well as shares reserved for future in-kind interest payments on the notes, were registered on a registration statement that was declared effective on May 11, 2023 (File No.333-271351).

 



 

 

 

 

 

 

 

 

 



 

 

 

 

 

 

 

 

 



 

September 30, 2017



 

Gross Carrying
Amount

 

Accumulated
Amortization

 

Net
Book Value

Patents and copyrights

 

$

19,322 

 

$

13,962 

 

$

5,360 

Prepaid licensing fees

 

 

574 

 

 

574 

 

 

 -



 

$

19,896 

 

$

14,536 

 

$

5,360 



 

 

 

 

 

 

 

 

 

10

Convertible notes payable at March 31, 2023 and December 31, 2022 consist of the following (in thousands):

 


           

Principal Outstanding as of

 
           March 31,  December 31, 

Description

 

Fixed Conversion Rate

  Interest Rate 

Maturity Date

 2023  2022 

Convertible notes dated September 10, 2018

 $0.40   8.0%

September 7, 2023

 $200  $200 

Convertible note dated September 19, 2018

 $0.57   8.0%

September 19, 2023

  425   425 

Convertible notes dated February/March 2019

 $0.25   8.0%

February 28, 2024 to March 13, 2024

  750   750 

Convertible notes dated June/July 2019

 $0.10   8.0%

June 7, 2024 to July 15, 2024

  295   295 

Convertible notes dated July 18, 2019

 $0.08   7.5%

July 18, 2024

  700   700 

Convertible notes dated September 13, 2019

 $0.10   8.0%

September 13, 2024

  50   50 

Convertible notes dated January 8, 2020

 $0.13   8.0%

January 8, 2025 1

  450   450 

Convertible notes dated May-August 2022

 $0.13   8.0%

May 10, 2027 to August 3, 2027

  1,468   1,668 

Convertible notes dated January 11, 2023

 $0.16   9.0%

January 11, 2028 1

  500   - 

Convertible notes dated January 13, 2023

 $0.16   9.0%

January 13, 2028

  200   - 

Total principal balance

           5,038   4,538 

Less current portion

           1,375   625 
           $3,663  $3,913 

1

The maturity date may be extended by one-year increments for up to an additional ten years at the holders’ option at a reduced interest rate of 2%.

At March 31, 2023, we estimate our convertible notes have an aggregate fair value of approximately $3.8 million and would be categorized within Level 2 of the fair value hierarchy.

 



 

 

 

 

 

 

 

 

 



 

 

 

 

 

 

 

 

 



 

December 31, 2016



 

Gross Carrying
Amount

 

Accumulated
Amortization

 

Net
Book Value

Patents and copyrights

 

$

19,499 

 

$

13,231 

 

$

6,268 

Prepaid licensing fees

 

 

574 

 

 

574 

 

 

 -



 

$

20,073 

 

$

13,805 

 

$

6,268 



 

 

 

 

 

 

 

 

 

11

9.  Secured Contingent Payment Obligation

 

The following table provides a reconciliation of our secured contingent payment obligation, measured at estimated fair market value, for the three months ended March 31, 2023 and the year ended December 31, 2022 (in thousands):


  

Three Months Ended March 31, 2023

  

Year Ended December 31, 2022

 

Secured contingent payment obligation, beginning of period

 $40,708  $37,372 

Change in fair value

  (1,805)  3,336 

Secured contingent payment obligation, end of period

 $38,903  $40,708 

Our secured contingent payment obligation represents the estimated fair value of our repayment obligation to Brickell Key Investments, LP (“BKI”Brickell”) under a February 2016 funding agreement, as amended in May 2016.  Under the agreement, we received aggregate proceeds of $13 million in exchange for BKI’s right to reimbursement and compensation from gross proceeds resulting from patent enforcement and other patent monetization actions. 

BKIamended.  Brickell is entitled to priority paymentpayments of 100% of proceeds received by us from all patent-related actions, after deduction of legal contingent fees, until such time that Brickell has been repaid its remaining principal.  As of March 31, 2023, Brickell's remaining principal was approximately $14.7 million.In May 2023, we repaid approximately $13.9 million of principal and borrowed an additional $5.0 million under the agreement, leaving $5.8 million in remaining outstanding principal.  After repayment of principal, Brickell is entitled to a portion of remaining proceeds received from all patent-related actions until such time that BKIBrickell has been repaid in full.  After repaymentits minimum return.  The minimum return is determined as a multiple of the funded amount BKI is entitled to a portion of remaining proceeds up to a specifiedthat increases over time.  The estimated minimum return which is determineddue to Brickell was approximately $59.3 million and $56.9 million as a percentage of the funded amountMarch 31, 2023 and varies based on the timing of repayment.December 31, 2022, respectively.  In addition, BKI isBrickell may be entitled to a pro rata portion of proceeds from specified legal actions to the extent aggregate proceeds from those actions exceed the specified minimum return.

8


BKI holds a senior security interest  The range of potential proceeds payable to Brickell is discussed more fully in our assets until such time as the specified minimum return is paid, in which case, the security interest will be released except with respect to the patents and proceeds related to specific legal actions.  The security interest is enforceable by BKI in the event that we are in default under the agreement which would occur if (i) we fail, after notice, to pay proceeds to BKI, (ii) we become insolvent or insolvency proceedings are commenced (and not subsequently discharged) with respect to us, (iii) our creditors commence actions against us (which are not subsequently discharged) that affect our material assets, (iv) we, without BKI’s consent, incur indebtedness other than immaterial ordinary course indebtedness, or (v) there is an uncured non-compliance of our obligations or misrepresentations under the agreement.Note 11.  As of September 30, 2017,March 31, 2023, we are in compliance with our obligations under this agreement.

 

We have elected to measure our secured contingent payment obligation at its estimated fair value based on probability-weighted estimated cash outflows, discounted back to present value using a discount rate determined in accordance with accepted valuation methods.methods (see Note 11).  The secured contingent payment obligation is remeasured to fair value at each reporting period with changes recorded in the condensed consolidated statements of comprehensive loss until the contingency is resolved.  As of September 30, 2017, the fair value of the obligation is estimated to be approximately $14.1 million (see Note 12).

 

10.  Share-Based Compensation

There has been no material change in the assumptions used to compute the fair value of our equity awards, nor in the method used to account for share-based compensation from those stated in our Annual Report on Form 10-K for the year ended December 31, 2016. Unsecured Contingent Payment Obligations

 

The following table presents share-based compensation expense includedprovides a reconciliation of our unsecured contingent payment obligations, measured at estimated fair market value, for the three months ended March 31, 2023 and the year ended December 31, 2022 (in thousands):


  Three Months Ended March 31, 2023  Year Ended December 31, 2022 

Unsecured contingent payment obligations, beginning of period

 $5,089  $5,691 

Change in fair value

  1,456   (602)

Unsecured contingent payment obligations, end of period

 $6,545  $5,089 

Our unsecured contingent payment obligations represent amounts payable to others from future patent-related proceeds including (i) a termination fee due to a litigation funder and (ii) contingent payment rights issued to accredited investors in ourconnection with equity financings (“CPRs”).  We have elected to measure these unsecured contingent payment obligations at their estimated fair value based on probability-weighted estimated cash outflows, discounted back to present value using a discount rate determined in accordance with accepted valuation methods.  The unsecured contingent payment obligations will be remeasured to fair value at each reporting period with changes recorded in the condensed consolidated statements of comprehensive loss foruntil the three and nine months ended September 30, 2017 and 2016, respectively (in thousands):contingency is resolved (see Note 11).

 



 

 

 

 

 

 

 

 

 

 

 

 



 

 

 

 

 

 

 

 

 

 

 

 



 

Three Months Ended

 

Nine Months Ended



 

September 30,

 

September 30,



 

2017

 

2016

 

2017

 

2016

Research and development expenses

 

$

89 

 

$

329 

 

$

499 

 

$

380 

Selling, general and administrative expenses

 

 

414 

 

 

1,094 

 

 

1,209 

 

 

1,108 

Total share-based compensation expense

 

$

503 

 

$

1,423 

 

$

1,708 

 

$

1,488 



 

 

 

 

 

 

 

 

 

 

 

 

12

As of September 30, 2017, we had approximately $1.6 million in unrecognized compensation cost related to unvested share-based compensation awards.  This cost is expected to be recognized over a weighted average period of approximately  one year.

11.  Stock Authorization and Issuance

On July 11, 2017, we amended our articles of incorporation to increase the number of authorized shares of common stock from 20 million to 30 million shares.  This amendment was approved by our shareholders on July 11, 2017.  Our shareholders also approved an amendment to our 2011 Long-Term Incentive Equity Plan to increase the shares authorized for issuance under the plan from 1.95 million to 3 million shares. 

On November 14, 2016, we filed a shelf registration statement (“Shelf”) for the offering of various securities, up to $15 million, over a period of up to three years.  The Shelf, which was declared effective

9


November 30, 2016, was intended to provide flexibility for our future capital needs.  On December 30, 2016, we entered into an ATM for the sale of up to $10 million of our common stock registered under the Shelf.  During the first quarter of 2017, we completed the sale of approximately 4.1 million shares of our common stock under the ATM at an average price of $2.46 per share for net proceeds of approximately $9.6 million after deduction of broker commissions, legal fees and expenses.    

On August 14, 2017, we entered into a new ATM agreement for the sale of up to approximately $4.4 million of our common stock registered under the Shelf.  As of September 30, 2017, we completed the sale of approximately 0.64 million shares of our common stock under the ATM at an average price of $1.85 per share for net proceeds of approximately $1.0 million after deduction of broker commissions, legal fees and expenses.   We had approximately $3.2 million remaining available for sale under the ATM as of September 30, 2017.

In February  2017,  we received proceeds of approximately $0.2 million from the sale of 80,510 unregistered shares of our common stock at a price of $2.11 per share to one of our directors.

Stock for Services

During the nine months ended September 30, 2017, we issued an aggregate of 0.3 million shares of unregistered common stock to two consultants in exchange for an aggregate of approximately $0.4 million in prepaid retainers for executive consulting and other advisory services.    We have no registration obligation with respect to these shares.

12. Fair Value Measurements

 

The following tables summarize the fair value of our assets and liabilitiescontingent payment obligations measured at fair value on a recurring basis as of September 30, 2017March 31, 2023 and December 31, 20162022 (in thousands):

 


      

Fair Value Measurements

 
  

Total Fair Value

  

Quoted Prices in Active Markets (Level 1)

  

Significant Other Observable Inputs (Level 2)

  

Significant Unobservable Inputs (Level 3)

 

March 31, 2023:

                

Liabilities:

                

Secured contingent payment obligation

 $38,903  $-  $-  $38,903 

Unsecured contingent payment obligations

  6,545   -   -   6,545 


      

Fair Value Measurements

 
  

Total Fair Value

  

Quoted Prices in Active Markets (Level 1)

  

Significant Other Observable Inputs (Level 2)

  

Significant Unobservable Inputs (Level 3)

 

December 31, 2022:

                

Liabilities:

                

Secured contingent payment obligation

 $40,708  $-  $-  $40,708 

Unsecured contingent payment obligations

  5,089   -   -   5,089 

 



 

 

 

 

 

 

 

 

 

 

 

 



 

 

 

 

 

 

 

 

 

 

 

 



 

 

 

 

Fair Value Measurements



 

Total Fair Value

 

Quoted Prices
in Active
Markets
(Level 1)

 

Significant
Other
Observable
Inputs
(Level 2)

 

Significant
Unobservable
Inputs
(Level 3)

September 30, 2017:

 

 

 

 

 

 

 

 

 

 

 

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

Restricted money market funds

 

$

153 

 

$

153 

 

$

 -

 

$

 -

Available-for-sale securities

 

 

101 

 

 

101 

 

 

 -

 

 

 -

Liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Secured contingent payment
   obligation

 

$

14,056 

 

$

 -

 

$

 -

 

$

14,056 



 

 

 

 

 

 

 

 

 

 

 

 

10




 

 

 

 

 

 

 

 

 

 

 

 



 

 

 

 

 

 

 

 

 

 

 

 



 

 

 

 

Fair Value Measurements



 

Total Fair Value

 

Quoted Prices
in Active
Markets
(Level 1)

 

Significant
Other
Observable
Inputs
(Level 2)

 

Significant
Unobservable
Inputs
(Level 3)

December 31, 2016:

 

 

 

 

 

 

 

 

 

 

 

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

Restricted money market funds

 

$

911 

 

$

911 

 

$

 -

 

$

 -

Available-for-sale securities

 

 

14 

 

 

14 

 

 

 -

 

 

 -

Liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Secured contingent payment
   obligation

 

$

14,185 

 

$

 -

 

$

 -

 

$

14,185 



 

 

 

 

 

 

 

 

 

 

 

 

For the three and nine months ended September 30, 2017, we had no transfers of assets or liabilities between the levels of the hierarchy.  The fair valuevalues of our secured and unsecured contingent payment obligation wasobligations were estimated using a probability-weighted income approach based on various cash flow scenarios as to the outcome of patent-related actions both in terms of timing and amount, discounted to present value using a risk-adjusted rate.  The contingent payment obligation does not have a fixed duration; however our cash flow projections assume a remaining duration ranging from approximately one to four years.  The cash outflows could potentially range from $0 to $32 million through 2021 and the cash flow scenarios have probabilities of 0% to 30%.  We used a risk-adjusted discount rate of 15.77%17.94% at March 31, 2023, based on a risk-free rate of 1.77%3.94% as adjusted by 8% for credit risk and 6% for litigation inherent risk.

The following table provides quantitative information about the significant unobservable inputs used in the measurement of fair value for both the secured and unsecured contingent payment obligations at March 31, 2023, including the lowest and highest undiscounted payout scenarios as well as a weighted average payout scenario based on relative undiscounted fair value of each cash flow scenario.


  

Secured Contingent Payment Obligation

  

Unsecured Contingent Payment Obligations

 

Unobservable Inputs

 

Low

  

Weighted Average

  

High

  

Low

  

Weighted Average

  

High

 
                         

Estimated undiscounted cash outflows (in millions)

 $13.9  $58.9  $102.9  $-  $9.7  $10.8 

Duration (in years)

  0.3   2.4   4.3   0.8   2.1   4.3 

Estimated probabilities

  5%  20%  35%  5%  22%  35%

We evaluate the estimates and assumptions used in determining the fair value of our contingent payment obligations each reporting period and make any adjustments prospectively based on those evaluations.  Changes in any of these Level 3 inputs could result in a significantly higher or lower fair value measurement.

 

The following table provides a reconciliation

13

12. Legal Proceedings

 

Secured Contingent
Payment Obligation

Balance at December 31, 2016

$

14,185 

Repayment

 -

Change in fair value

(129)

Balance at September 30, 2017

$

14,056 

 13.  Commitments and Contingencies

Lease Commitments

In April 2017, we entered into a new lease agreement for our Lake Mary, Florida facility with a lease commencement date of July 1, 2017.  The lease provides for a straight-lined monthly base rental payment of approximately $13,000  through November 2022 with an option for renewal. 

In July 2017, we entered into a new lease agreement for warehouse and assembly space in Jacksonville, Florida.  The lease provides for a straight-lined monthly base rental payment of approximately $2,000 through July 2020 with options for expansion and renewal.

11


In July 2017, we also amended the lease for our existing Jacksonville, Florida facility to extend the lease expiration date from January 15, 2018 to July 15, 2018.  The lease provides for a straight-lined monthly base rental payment of approximately $28,000 through July 2018.

Legal Proceedings

From time to time, we are subject to legal proceedings and claims which arise in the ordinary course of our business.  These proceedings include patent enforcement actions initiated by us against others for the infringement of our technologies, as well as proceedings brought by others against us at the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office (“PTAB”) in an attempt to invalidate certain of our patent claims.   These patent-related proceedings are more fully described below.Although there is at least a reasonable possibility of an unfavorable outcome in any one or more of these matters, we believe that any such outcome is not expected to have a material impact on our financial position or results of operations.

 

The majority of our litigation, including our PTAB proceedings, is being paid for through contingency fee arrangements with our litigation counsel as well as third-party litigation financing.  In general, litigation counsel is entitled to recoup on a priority basis, from litigation proceeds, any out-of-pocket expenses incurred.  Following reimbursement of out-of-pocket expenses, litigation counsel is generally entitled to a percentage of remaining proceeds based on the terms of the specific arrangement between us, counsel and our third-party litigation funder.

ParkerVision v. Qualcomm and HTC (Middle District of Florida)Florida-Orlando Division) - Appealed to U.S. Court of Appeals for the Federal Circuit

We have aappealed certain March 2022 rulings by the Middle District of Florida in our patent infringement complaint pendingagainst Qualcomm Incorporated and Qualcomm Atheros, Inc. (collectively “Qualcomm”).  Appellate court briefs have been filed by both parties and we are awaiting a hearing date in this matter. 

The patent infringement case was filed in the Middle District of Florida against Qualcomm and Qualcomm Atheros, Inc. (collectively “Qualcomm”), and HTC (HTC Corporation and HTC America, Inc.) (the “Qualcomm Action”) seeking unspecified damages and injunctive relief for infringement of certain of our patents.  Certain of the defendants have filed counterclaims against us for non-infringement and invalidity for all patents in the case.  A claim construction hearingMay 2014.  The case was heldstayed in August 2015 but no ruling on claim construction has been issued by the court.  In February 2016 the court granted the parties’ joint motion to stay these proceedings until resolution of the proceedings at the International Trade Commission (“ITC”) as discussed below.  In May 2017, we filed a motion to continue the stay of these proceedings pending andecisions in other cases, including the appeal of certaina PTAB decisionsproceeding with regard to our ‘940 Patent as discussed below.

Qualcomm v. ParkerVision (PTAB)

In August 2015, Qualcomm filed an aggregate of ten petitions for Inter Partes Review (“IPR”) with U.S. patent 6,091,940 ("the PTAB seeking to invalidate certain claims related to three of the eleven patents originally'940 Patent") asserted in our Qualcomm Action.this case.  In March 2016, the PTAB issued decisions denying institution of trial for three of the petitions, all of which relate to our U.S. patent 7,039,372 (“the ‘372 Patent”).  The remaining petitions, all of which relate to our U.S. patent 6,091,940 (“the ‘940 Patent”) and U.S. patent 7,966,012 (“the ‘012 Patent”) were instituted for trial by the PTAB.    In May 2016, the PTAB granted our motion to disclaim the challenged claims of the ‘012 Patent and entered an adverse judgment against us with respect to those claims. In March 2017, the PTAB issued its decisions on the six outstanding IPRs, all of which relate to the ‘940 Patent.  The PTAB ruled in our favor on three of the six petitions (the method claims), ruled in Qualcomm’sQualcomm's favor on two of the six petitions (the apparatus claims) and issued a split decision on the claims covered in the sixth petition.  In September 2018, the Federal Circuit upheld the PTAB's decision with regard to the '940 Patent and, in January 2019, the court lifted the stay in this case.  In July 2019, the court issued an order that granted our proposed selection of patent claims from four asserted patents, including the '940 Patent, and denied Qualcomm's request to limit the claims and patents.  The court also agreed that we may elect to pursue accused products that were at issue at the time the case was stayed, as well as new products that were released by Qualcomm during the pendency of the stay.  In September 2019, Qualcomm filed a motion for partial summary judgment in an attempt to exclude certain patents from the case, including the '940 Patent.  The court denied this motion in January 2020.

In April 2020, the court issued its claim construction order in which the court adopted our proposed construction for seven of the ten disputed terms and adopted slightly modified versions of our proposed construction for the remaining terms.  Due to the impact of COVID-19, a number of the scheduled deadlines in this case were moved, including the trial commencement date which was rescheduled from December 2020 to May 2021.  In October 2020, our damages expert submitted a report supporting our damages ask of $1.3 billion for Qualcomm's unauthorized use of our technology.  Such amount excludes additional amounts requested by us for interest and enhanced damages for willful infringement.  Ultimately, the amount of damages, if any, will be determined by the court.  Discovery was expected to close in December 2020; however, the court allowed us to designate a substitute expert due to medical issues with one of our experts in the case.  Accordingly, the close of discovery was delayed until January 2021.  As a result of these delays, the court rescheduled the trial commencement date from May 3, 2021 to July 6, 2021.

In March 2021, the court further delayed the trial date citing backlog due to the pandemic, among other factors.  A new trial date was not set and the court indicated the case was unlikely to be tried before November or December 2021.  Fact and expert discovery was completed, expert reports were submitted, and summary judgment and Daubert briefings were submitted by the parties.  Joint pre-trial statements were submitted in May 2021.  In March 2021, the court granted Qualcomm's motion to strike certain of our 2020 infringement contentions.  As a result of this ruling, in July 2021, we filed a joint motion for entry of a judgment of non-infringement of our Patent No.7,865,177 ("the '177 Patent"), subject to appeal.

14

In January 2022, the court held a hearing to allow the parties to present their respective positions on three outstanding motions.  The court indicated that upon its ruling on these motions, a pre-trial conference would be scheduled and a trial date set.  On March 9, 2022, the court ruled with respect to one of these motions granting Qualcomm’s motion to strike and exclude opinions regarding the alleged infringement and validity issues.  This court order precluded the presentation of infringement and validity opinions by both of our experts at trial. On March 22, 2022, the court issued an order granting Qualcomm’s motion for summary judgment ruling that Qualcomm does not infringe the remaining three patents in this case.  On April 20, 2022, we filed a notice of appeal to the United States Court of Appeals for the Federal Circuit.  As a result of the PTAB decisions, certain claimscourt’s summary judgment motion in favor of Qualcomm, Qualcomm has the ‘940 Patent whichright to petition the court for its fees and costs. The court has granted a Qualcomm motion to delay such a petition until 30 days following the appellate court’s decision.  We are the subject of our district courtrepresented in this case against Qualcomm and HTC were found to be un-patentable.  In May 2017, we filed our notice of appeal of these decisions with the Federal Circuit.  Qualcomm also appealed the decisions that were unfavorable to them.on a full contingency fee basis.

 

ParkerVision v. Apple and Qualcomm (ITC and(Middle District of Florida-Jacksonville Division)

In December 2015, we filed a patent infringement complaint in the Middle District of Florida)

In December 2015, we filed a complaint with the U.S. ITCFlorida against Apple Inc. (“Apple”), LG Electronics, Inc., LG Electronics U.S.A., Inc., and LG Electronics MobileComm U.S.A., Inc. (collectively “LG”), Samsung Electronics Co., Ltd., Samsung Electronics America, Inc., Samsung Telecommunications America LLC, and Samsung Semiconductor, Inc. (collectively “Samsung”), and Qualcomm alleging that these companies make, use or sell products that infringe certain of our patent claims and requesting that the ITC bar the defendants from continuing to import and sell infringing products in the U.S.  We filed a corresponding patent infringement complaint in the Middle District of Florida against these same defendants alleging infringement of four of our patents.  In January

12


2016, the ITC instituted an investigation based on our complaint. In February 2016, the district court proceedings were stayed pending resolution of the proceedingsa corresponding case filed at the ITC.International Trade Commission (“ITC”).  In July 2016, we entered into a confidential patent license and settlement agreement with Samsung and, as a result, Samsung was removeddismissed from both the ITC and the related district court action.  In JanuaryMarch 2017, we dismissed three of the four patents from the case in order to simplify the investigation.  On March 10, 2017, the administrative law judge issued a ruling on a pre-trial motion that precluded us from presenting key evidence in our case.  As a result, on March 13, 2017, we filed a motion to terminate the proceedings at the ITC.  On April 28, 2017, the ITC granted our motion to withdraw from the ITC proceedings. 

Following the termination of the ITC proceedings we filedand a corresponding motion to lift the stay in the district court case. This motion was granted on in May 25, 2017. On In July 21, 2017, we filed a motion to dismiss LG from the district court case and re-filed our claims against LG in the District of New Jersey (see ParkerVision v. LG below).  Also in July 2017, Qualcomm filed a motion to change venue to the Southern District of California, and Apple filed a motion to dismiss for improper venue. In March 2018, the district court ruled against the Qualcomm and Apple motions. The court has setparties also filed a joint motion in March 2018 to eliminate three of the four patents in the case in order to expedite proceedings leaving our U.S. patent 9,118,528 as the only remaining patent in this case.  A claim construction hearing was held on August 31, 2018. In July 2019, the court issued its claim construction order in which the court adopted our proposed claim construction for two of the six terms and the “plain and ordinary meaning” on the remaining terms. In addition, the court denied a motion filed by Apple for summary judgment.  Fact discovery has closed in this case and a jury trial was scheduled to begin in August 2020.  In March 2020, as a result of the impact of COVID-19, the parties filed a motion requesting an extension of certain deadlines in the remainingcase.  In April 2020, the court stayed this proceeding pending the outcome of the infringement case against Qualcomm and Apple for mid-January 2018.     in the Orlando Division of the Middle District of Florida, which is currently pending an appeal.  

 

ParkerVision v. LG (District of New Jersey)

On In July 21, 2017, we filed a patent infringement complaint in the districtDistrict of New Jersey against LG for the alleged infringement of the same four patents previously asserted against LG in the middle districtMiddle District of Florida (see ParkerVision v. Apple and Qualcomm above). We elected to dismiss the case in the middle districtMiddle District of Florida and re-file in New Jersey as a result of a recent Supreme Court ruling regarding proper venue. No trial dates have yet been establishedIn March 2018, the court stayed this case pending a final decision in ParkerVision v. Apple and Qualcomm in the Middle District of Florida. As part of this stay, LG has agreed to be bound by the final claim construction decision in that case.

 

ParkerVision v. LG Electronics (Munich, Germany)Intel (Western District of Texas)

In June 2016, February 2020, we filed a patent infringement complaint in Munich Regional Courtthe Western District of Texas against LG Electronics Deutschland GmbH, a German subsidiary of LG Electronics, Inc.Intel Corporation (“LGE”Intel”) seeking damages and injunctive relief for the allegedalleging infringement of oneeight of our German patents. A hearingThe complaint was amended in May 2020 to add two additional patents. In June 2020, we requested that one of the patents be dropped from this case and filed a second case in the Western District of Texas that included this dismissed patent (see ParkerVision v. Intel II below). Intel’s response to our complaint was filed in June 2020 denying infringement and claiming invalidity of the patents. Intel also filed a motion to transfer venue which was denied by the court.  In July 2020 and September 2020, Intel filed petitions for Inter PartesReview (“IPR”) against two of the patents in this case and in January 2021, the PTAB instituted proceedings with regard to these two petitions (see Intel v. ParkerVision (PTAB) below).

15

The court issued its claim construction ruling in January 2021 in which the majority of the claims were decided in our favor.  The case was heldscheduled for trial beginning February 7, 2022.  In April 2021, we filed an amended complaint to include additional Intel semiconductors and products, including WiFi devices, to the complaint.  The court suggested that, given the number of patents at issue, the case would be separated into two trials and, as a result of the added products, the first trial date was scheduled for June 2022.

In January 2022, the PTAB issued its ruling on the IPRs (see Intel v. ParkerVision (PTAB) below).  In February 2022, the parties filed a joint motion with respect to both Intel cases whereby the first case would be narrowed to six total patents asserted against Intel cellular products.  These same six patents would be also asserted in November 10, 2016.  On November 14, 2016,the second Intel case, along with one additional patent from the second case, against Intel WiFi and Bluetooth products.  As a result of the restructuring of the two cases, the trial date was moved to October 2022.  In March 2022, due to discovery delays, the court concluded that certain LGE products using Qualcomm RF circuitry infringe our patent.  Subjectagreed to successful completion ofmove the co-pending nullity action intrial commencement date to December 5, 2022.  In March 2022, Intel filed a motion requesting further claim construction which we opposed and the German Federal Patent Court in Munich, the regional court will enjoin the sale and importation of these LGE products in Germany.  The court has not yet ruled on the nullity action, which is a validity only challenge.

ParkerVision v. Apple (Munich, Germany)

denied.  In October 2016, May 2022, we filed a motion to amend our complaint to add willful infringement based on information obtained during discovery.  The court granted this motion in June 2022 and we filed an amended complaint. As a result of additional discovery allowed by the court, the trial date was rescheduled from December 5, 2022 to February 6, 2023. 

Beginning in November 2022, the parties filed a number of pre-trial motions.  The court held hearings on these pre-trial motions in January 2023.  The court issued its written orders with regard to these motions immediately prior to the February 6, 2023 trial start date.  As a result of the court's pre-trial rulings, the potential damages in the case decreased significantly.  On February 7, 2023, the parties resolved their outstanding dispute and we have dismissed all pending actions against Intel.

ParkerVision v. Intel II (Western District of Texas)

In June 2020, to reduce the number of claims in ParkerVision v. Intel, we filed a second patent infringement complaint in Munich Regional Courtthe Western District of Texas against Apple, Inc., Apple Distribution International, and Apple Retail Germany B.V. & Co. KG (collectively “Apple”) seeking damages and injunctive relief forIntel that included one patent that we voluntarily dismissed from the alleged infringement of the same German patent as in the LGE case (the “Apple I” case).original case.  In February 2017, July 2020, we amended our complaint adding two more patents to the case.  Intel responded to the complaint denying infringement and claiming invalidity of the patents.  In January 2021, Intel filed a second German patentpetition for IPR against one of the patents in this case and alleging infringement by Apple devicesin July 2021, the PTAB instituted proceedings with regard to this petition (see Intel v. ParkerVision (PTAB) below).  We filed an amended complaint in 2021 adding Intel WiFi and Bluetooth products to the case.  Two claim construction hearings were held in June 2021 and July 2021 and the court’s claim construction ruling was largely decided in our favor.  The case was scheduled for trial in October 2022.  In February 2022, the parties filed a joint motion which provided that incorporate an the Intel transceiver chip.  The Munich Regional Court has bifurcatedII case would assert the new claims into a second case separatesame six patents from the original Applefirst Intel case, (the “Apple II” case)provided none of the patents were invalidated in the first case, as well as one additional patent, depending on the outcome of the pending IPR proceeding.  On February 7, 2023, the parties resolved their outstanding dispute and we have dismissed all pending actions against Intel.

Intel v. ParkerVision (PTAB)

Intel filed IPR petitions against U.S. patent 7,539,474 (“the ‘474 Patent”) and U.S. patent 7,110,444 (“the ‘444 Patent”) which were both asserted in ParkerVision v. IntelAIntel also filed a petition for IPR against U.S. patent 8,190,108 (“the ‘108 Patent”), which is asserted in ParkerVision v. Intel II. In January 2021, the PTAB issued its decision to institute IPR proceedings for the ‘444 Patent and the ‘474 Patent.  An oral hearing was held on May 4, 2017November 1, 2021 and final decisions from the PTAB on the ‘474 Patent and the ‘444 Patent were issued in January 2022.  The PTAB ruled against us with respect to the Apple I case.   On June 22, 2017,single challenged claim of the court deferred’444 Patent and ruled in our favor with respect to the seven challenged claims of the ‘474 Patent.  The ‘444 Patent has subsequently been excluded from the narrowed claims asserted in ParkerVision v. Intel.  In July 2022, we appealed the PTAB decision on the '444 Patent to the Federal Circuit. 

In July 2021, the PTAB issued its ruling pendingdecision to institute IPR proceedings for the validity‘108 Patent.  We filed our response to this petition in October 2021 and an oral hearing was scheduled for April 2022.  A final decision from the GermanPTAB was issued in June 2022 in which the PTAB ruled against us with respect to all of the challenged claims of the ‘108 Patent.  We filed a notice of appeal with the Federal Patent CourtCircuit with respect to this IPR decision.  Following the parties' resolution of outstanding disputes (see ParkerVision v. LG ElectronicsIntel above)., Intel withdrew as a party to these appeals. The Apple II case is scheduled for a hearing on November U.S. Patent and Trademark Office ("USPTO") has exercised its right to intervene following Intel's withdrawal and defend the PTAB's decisions. 

16 2017.  In August 2017, Intel

Additional Patent Infringement Cases Western District of Texas

ParkerVision filed a nullity actionnumber of additional patent cases in the German Federal Patent CourtWestern District of Texas in 2020 including cases against (i) TCL Industries Holdings Co., Ltd, a Chinese company, TCL Electronics Holdings Ltd., Shenzhen TCL New Technology Co., Ltd, TCL King Electrical Appliances (Huizhou) Co., Ltd., TCL Moka Int’l Ltd. and TCL Moka Manufacturing S.A. DE C.V. (collectively “TCL”), (ii) Hisense Co., Ltd. and Hisense Visual Technology Co., Ltd (collectively “Hisense”), a Chinese company, (iii) Buffalo Inc., a Japanese company (“Buffalo”) and (iv) Zyxel Communications Corporation, a Chinese multinational electronics company headquartered in Taiwan, (“Zyxel”).  Each case alleges infringement of the same ten patents by products that incorporate modules containing certain WiFi semiconductors manufactured by Realtek and/or MediaTek.  In May 2021, a case alleging infringement of the same ten patents was filed against LG Electronics, a South Korean company ("LGE").  Each of the defendants have filed responses denying infringement and claiming invalidity of the patent that is the subjectpatents, among other defenses.  A second case was filed against Hisense in June 2021 alleging infringement of two additional patents and a second case was filed against TCL in November 2022 alleging infringement of the Apple II infringement case. same two additional patents. 

 

14.  Subsequent EventsIn November 2022, patent infringement actions were also filed against Taiwanese companies, Realtek Semiconductor Corp. ("Realtek") and MediaTek Inc. and MediaTek USA Inc. (collectively, "MediaTek") for infringement of four U.S. patents that are included in other Texas cases.

 

On October 17, 2017, We dismissed the actions against Buffalo and Zyxel in 2021 following satisfaction of the parties' obligations under patent license and settlement agreements.  In November 2022, we sold 312,500 sharesdismissed the two cases against Hisense following satisfaction of common stock at $1.60 per share for proceeds of $0.5 millionthe parties' obligations under a purchase agreement with Aspire Capital Fund, LLC (“Aspire Capital”).  patent license and settlement agreement.

The court has issued claim construction recommendations for the TCL and LGE cases, in which nearly all of the claim terms were decided in our favor.  In November 2022, the PTAB issued its written decision in two IPRs asserted by TCL and LGE against two of the patents asserted against them (see TCL, et. al. v. ParkerVision (PTAB) below. 

In January 2023, the cases against TCL were stayed pending final resolution of the Realtek case that was filed in November 2022.  In addition, Aspire Capital committedin February 2023, the case against LGE was stayed pending final resolution of the cases against Realtek and MediaTek and the outstanding IPR actions to which LGE is a party.

TCL, et. al. v. ParkerVision (PTAB)

In May 2021, TCL, along with Hisense, filed petitions for IPR against U.S. patent 7,292,835 (“the ‘835 Patent”) and the ‘444 Patent, both of which are asserted in the infringement cases against these parties in the Western District of Texas.  In November 2021, the PTAB issued its decision to implement IPR proceedings for these two patents.  In December 2021, LGE filed nearly identical petitions against the same two patents along with a joinder motion requesting to join the existing petitions filed by TCL and Hisense.  In April 2022, the PTAB granted LGE’s joinder motion.  Oral hearings for these IPRs were held in September 2022.  As part of a patent license and settlement agreement entered into with Hisense in November 2022, Hisense withdrew its participation in these IPR proceedings.  In November 2022, the PTAB issued its written decision ruling that the challenged claims for both patents were unpatentable.  We have appealed these decisions.

13. Stock Authorization and Issuance

Stock Issuances – Equity Based Financings

Private Placements with Accredited Investors

In January 2023, we entered into securities purchase up toagreements with accredited investors for the sale of an aggregate of $20 million of843,750 shares of our common stock at a price of $0.16 per share for aggregate proceeds of $0.14 million, including 62,500 shares to Sanford Litvack, a member of our Board of Directors.  The shares were registered for resale on a registration statement that was declared effective on May 11, 2023 (File No.333-271351).

17

Common Stock Warrants

As of March 31, 2023, we had outstanding warrants for the purchase of up to 10.3 million shares of our common stock.  The estimated grant date fair value of these warrants of $3.2 million is included in additional paid-in capital in our condensed consolidated balance sheets. As of March 31, 2023, our outstanding warrants have an average exercise price of $0.75 per share and a weighted average remaining life of approximately 1.9 years. 

14. Share-Based Compensation

There has been no material change in the assumptions used to compute the fair value of our equity awards, nor in the method used to account for share-based compensation from those stated in our 2022 Annual Report.

For the three months ended March 31, 2023 and 2022, we recognized share-based compensation expense of approximately $0.2 million and $0.75 million, respectively.  Share-based compensation is included in selling, general and administrative expenses in the accompanying condensed consolidated statements of comprehensive income.  As of March 31, 2023, there was $0.4 million of total unrecognized compensation cost related to all non-vested share-based compensation awards.  The cost is expected to be recognized over the 30-month terma weighted-average remaining life of approximately 0.9 years.

15. Income Taxes

The Company's effective income tax rate was 0.0% for each of the agreement, three months ended March 31, 2023 and 2022.  The 0.0% effective rate for 2023 is due to NOL carryforwards not previously recognized as a tax benefit that we issued 287,500expect to be able to utilize in the current year to offset income tax expense related to current period income.

16. Related Party Transactions

On January 13, 2023, we sold 62,500 shares of our common stock to Aspire Capital asSanford Litvack, one of our directors since October 2022, at $0.16 per share in a commitment fee under this agreement.   Concurrent with entering into the purchaseprivate placement transaction (see Note 13).   

1317. Subsequent Events


 

agreement with Aspire Capital, On May 4, 2023, we also entered into a registration rightsconfidential letter agreement with Brickell whereby we agreedBrickell provided $5.0 million in new funding to file a registration statement registering the sale of the shares of our common stock that have been and may be issued to Aspire Capital under the agreement.   Our registration statementus on Form S-1, filed on October 31, 2017, has not yet been declared effective by the SEC.

Under the agreement, after the registration statement has been declared effective, on any trading day selected by us, we have the right,substantially similar repayment terms as those set forth in our sole discretion, to present Aspire Capitalexisting contingent payment agreement with a purchase notice, directing Aspire Capital to purchase up to 150,000shares of our common stock , provided that the aggregate purchase amount for such shares does not exceed $0.5 million and subject to the maximum aggregate amount of $20 millionBrickell, but at a per share purchase price equal tolower interest rate.  We will use the lesser of (i) the lowest sale price of our common stock on the purchase date; or (ii) the arithmetic average of the three lowest closing sale pricesproceeds for our common stock during the ten consecutive trading days ending on the trading day immediately preceding the purchase date.

In addition, on any date on which we submit a purchase notice to Aspire Capital, we also have the right, in our sole discretion, to present Aspire Capital with a volume-weighted average price (“VWAP”) purchase notice directing Aspire Capital to purchase an amount of stock equal to up to 30% of the aggregate shares of our common stock traded on its principal market on the next trading day, subject to a maximum number of shares we may determine.  The purchase price per share pursuant to the VWAP purchase notice isgenerally 97% of the volume-weighted average price for our common stock traded on its principal market on the VWAP purchase date, subject to terms and limitations of the agreement.working capital purposes.  

 

14

18

ITEMITEM 2. Management’sManagements Discussion and Analysis of Financial Condition and Results of Operations

 

Forward-Looking Statements

 

We believe that it is important to communicate our future expectations to our shareholders and to the public.  This quarterly report contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, including, in particular, statements about our future plans, objectives, and expectations contained in this Item.  When used in this quarterly report and in future filings by us with the Securities and Exchange Commission (“SEC”), the words or phrases “expects”, “will likely result”, “will continue”, “is anticipated”, “estimated” or similar expressions are intended to identify “forward-looking statements.”  Readers are cautioned not to place undue reliance on such forward-looking statements, each of which speaks only as of the date made. Such statements are subject to certain risks and uncertainties that could cause actual results to differ materially from historical results and those presently anticipated or projected, including the risks and uncertainties identified in our annual report on Form 10-K for the fiscal year ended December 31, 20162022 (the “Annual“2022 Annual Report”) and in this Item 2 of Part I of this quarterly report.  Examples of such risks and uncertainties include general economic and business conditions, competition, unexpected changes in technologies and technological advances, the timely development and commercial acceptance of new products and technologies, reliance on key business and sales relationships,suppliers, reliance on our intellectual property, the outcome of our intellectual property litigation and the ability to obtain adequate financing in the future.  We have no obligation to publicly release the results of any revisions which may be made to any forward-looking statements to reflect anticipated events or circumstances occurring after the date of such statements.

 

Corporate Website

 

We webcast our earnings calls and certain events we participate in or host with members of the investment community in the investor relations section of our website. Additionally, we announce investor information, including news and commentary about our business, financial performance and related matters, SEC filings, notices of investor events, and our press and earnings releases, in the investor relations section of our website (http:(http://ir.parkervision.com)ir.parkervision.com).  Additionally, if applicable, we webcast our earnings calls and certain events we participate in or host with members of the investment community in the investor relations section of our website.  Investors and others can receive notifications of new information posted in the investor relations section in real time by signing up for email alerts and/or RSS feeds. Further corporate governance information, including our governance guidelines, board of directors (“Board”) committee charters, and code of conduct, is also available in the investor relations section of our website under the heading “Corporate Governance.”  The content of our website is not incorporated by reference into this quarterly reportQuarterly Report or in any other report or document we file with the SEC, and any references to our website are intended to be inactive textual references only.

 

Overview

 

We are in the business of innovating fundamental wireless technologieshave invented and products.   We have designed and developed a consumer and small business distributed Wi-Fi product line that is being marketed under the brand name Milo™.  We also design, develop and market our proprietary radio frequency (“RF”) technologies and integrated circuits based on those technologies, and we license those technologies to third parties for use in semiconductor circuits for wireless communication products, including our own internally developed products.  We have expended significant financial and other resources to research and develop our RF technologies and to obtain patent protection for those technologies in the United States of America (“U.S.”) and certain foreign jurisdictions.  We believe certain patents protecting our proprietary technologies have been broadly infringed by others and therefore the primary focus of our business plan includesis the enforcement of our intellectual property rights through patent licensing and infringement litigation efforts.  We currently have patent enforcement actions ongoing in various U.S. district courts against mobile handset, smart television, and licensing efforts.

15


We have a growth strategy that includes wirelessother WiFi product development, manufacturing and sales and intellectual property licensing and enforcement.  Our longer-term strategy is expected to includeproviders, as well as semiconductor suppliers, for the acquisitioninfringement of or other product ventures with, companies that have businesses that are synergistic withseveral of our products and technologies, particularly in the IoT, or Internet of Things, space.RF patents.  We have made significant investments in developing and protecting our technologies, and products, the returns on which are dependent upon the generation of future revenues from product sales and/or licensing for realization.

Recent Events

 

Recent Developments

Wi-Fi Product IntroductionLegal Proceedings

In October 2017,February 2023, we commenced sales of our new homeentered into a confidential patent license and small business networking product line under the tradename, Milo™.  We currently offer twosettlement agreement and three unit systems through online sales channels that include Amazon and our own online store, www.milowifi.com.  

Nasdaq Compliance

On August 11, 2017,in March 2023, we received a notice from the Listing Qualifications Departmentpayment of Nasdaq stating that,$25 million with respect thereto.  These proceeds were fully utilized for the last 30 consecutive business days, the market valuerepayment of the Company’s listed securities (“MVLS”) had been below the minimum of $35 million required for continued inclusion on the Capital Market under Nasdaq Listing Rule 5550(b)(2). The notification letter stated that we would be afforded 180 calendar days, or until February 7, 2018, to regain compliance.  In order to regain compliance, the Company’s MVLS must remain at $35 million or more for a minimum of ten consecutive business days.  The notification letter also stated that in the event we do not regain compliance within the 180 day period, our securities may be subject to delisting.

Liquidity and Capital Resources

At September 30, 2017, our capital resources consisted of approximately $0.4  million in cash, restricted cash equivalents and available-for-sale securities and approximately $0.2 million in restricted cash equivalents.     

We used cash for operations of approximately $11.0 and $11.8 million for the nine month periods ended September 30, 2017 and 2016, respectively.  The decrease in cash used for operations is primarily the result of a decrease in payments for litigationcontingent legal fees and expenses which are paid from restricted cash equivalents, somewhat offset by increasesand outstanding principal on our contingent payment obligation with Brickell repaid in operating and inventory costs relatedMay 2023 (see “Brickell Agreement” below).

In February 2023, we dismissed our two patent enforcement actions against Intel Corporation. Refer to Note 12 to our consolidated financial statements included elsewhere in this prospectus for a complete discussion of our patent enforcement proceedings.

Brickell Agreement

We repaid Brickell $13.9 million in May 2023 from our patent licensing and settlement proceeds.  On May 4, 2023, we entered into a confidential letter agreement with Brickell whereby Brickell provided $5.0 million in new consumer product launch.  Our usefunding to us on substantially similar repayment terms as those set forth in our existing contingent payment agreement, but at a lower interest rate.  The new funding will be used for operations.  

Other Debt and Equity Financings

In January 2023, we received proceeds of cash for the nine months ended September 30, 2017 was largely funded from the proceedsapproximately $0.7 million from the sale of five-year convertible notes to accredited investors.  The notes are convertible, at the holders' option, into shares of our equity securities under At Market Issuance Sales Agreements (“ATM”).  We anticipate revenuescommon stock at a fixed conversion price of $0.16 per shares and margin generated by our consumer product will begin to offset our operating costs in the fourth quarterbear interest at a stated rate of 2017, however the revenues and margins generated in the short-term will not be sufficient to fully fund our operations without the need for additional working capital.  Our capital resources at September 30, 2017 are not sufficient to support our working capital requirements for the next twelve months which raises substantial doubt about our ability to continue as a going concern.

16


We have approximately $3.2 million remaining available under our ATM agreement at September 30, 2017,9% per annum.  Interest is payable quarterly, and we intendmay elect, subject to use thecertain equity conditions, to pay interest in cash, shares of our common stock, or a combination thereof.  In addition, in January 2023, we received aggregate proceeds of approximately $0.14 million from the sale of common stock to accredited investors, including 62,500 shares to Sanford Litvack, a member of our Board of Directors, at a price of $0.16 per share.  The shares were registered for resale on a registration statement that was declared effective on May 11, 2023 (File No. 333-271351).

Liquidity and Capital Resources

We generated cash and restricted cash from operations of approximately $13.2 million for the three months ended March 31, 2023 and used cash for operations of $0.9 million for the three months ended March 31, 2022.  The increase in cash generated from operations from 2022 to 2023 is primarily due to proceeds received from the patent license and settlement agreement entered into in February 2023, net of contingent legal fees and expenses paid.  At March 31, 2023, we had cash and cash equivalents of approximately $0.1 million and restricted cash of approximately $13.9 million.  The restricted cash was used to make a $13.9 million repayment of principal on our secured contingent payment obligation in May 2023.    

For the three months ended March 31, 2023, we received aggregate net proceeds from the sale of debt and equity securities, including the exercise of outstanding options and warrants, of approximately $0.8 million compared to approximately $0.1 million in proceeds received for the three months ended March 31, 2022.  We repaid approximately $0.04 million and $0.02 in debt obligations during the three months ended March 31, 2023 and 2022, respectively.  In May 2023, we repaid $13.9 million on our secured contingent payment obligation and received $5.0 million in new funding under thisthat agreement to fund(see Note 17). 

We believe our short-term workingcurrent capital needs.   Our abilityresources are sufficient to meet our liquidity needs for at least the next twelve months is dependent upon (i) our ability to develop, market and sell existing and new products; (ii) our ability to successfully negotiate licensing agreements and/or settlements relating to the use of our technologies by others in excess of our contingent payment obligations; and/or (iii) our ability to obtain additional debt or equity financing.  We expect that revenue generated from product sales, patent enforcement actions, and technology licenses over the next twelve months may not be sufficient to cover our working capital requirements.   In the event we do not generate sufficient revenues to cover our operational costs and contingent repayment obligations, we will not be required to use available working capital and/or raiseseek additional working capital through the salecapital.  

 

We expect to continue to invest in the support of our patent prosecutionlicensing and enforcement product development,program. A significant amount of future proceeds that we may receive from our patent licensing and sales, marketing,enforcement program will be first utilized to repay borrowings and customer support forlegal fees and expenses under our technologies and products.contingent funding arrangements.  The long-term continuation of our business plan is dependent upon the generation of sufficient revenuescash flows from our technologies and/or products to offset expenses and contingent paymentdebt obligations.  In the event that we do not generate sufficient revenues,cash flows, we will be required to obtain additional funding through public or private debt or equity financing or contingent fee arrangements and/or reduce operating costs.  Failure to generate sufficient revenues,cash flows, raise additional capital through debt or equity financings or contingent fee arrangements, and/or reduce operating costs will have a material adverse effect on our ability to meet our long-term liquidity needs and achieve our intended long-term business objectives.

 

Results of Operations for Each of the Three and Nine Months Ended September 30, 2017 and 2016

We use both generally accepted accounting principles (“GAAP”) and non-GAAP financial measures for assessing our consolidated results of operations.  The non-GAAP measures we use include Adjusted Net Loss and Adjusted Net Loss per Share.  These non-GAAP measures exclude the effect on net loss and net loss per share of (i) changes in fair value of our secured contingent payment obligation and (ii) share-based compensation expense.  Share-based compensation is a non-cash expense item that is subject to significant fluctuation in value based on the volatility of the market price of our common stock, and the expense recognized on a GAAP basis is not necessarily indicative of the compensation realized by our executives, employees and non-employee directors.   The change in fair value of our secured contingent payment obligation is subject to significant estimates and assumptions regarding future events and, similar to interest on long-term debt obligations, is a reflection of our cost of financing rather than our operating activities.  Accordingly, we consider these non-GAAP measures to provide relevant supplemental information to assist investors in better understanding our operating results.  These non-GAAP measures should not be considered a substitute for, or superior to measures of financial performance prepared in accordance with GAAP. 

Refer to “Reconciliation of Non-GAAP Financial Measures” in this section for a reconciliation of these non-GAAP financial measures to the most directly comparable GAAP measures for the three and nine months ended September 30, 2017 and 2016.

Revenue and Gross Margin

Our revenue decreased approximately $4.0 million during the three and nine month periods ended September 30, 2017 when compared to the same period in 2016.  Our gross margin decreased approximately $3.7 million during the three and nine month periods ended September 30, 2017 when compared to the same period in 2016.  The decrease in revenue and margin for both the three and nine month periods is the result of licensing and settlement revenue and related cost recognized in the third quarter of 2016 that is not recurring in 2017.   We began shipments of our Milo Wi-Fi consumer products

17


in October 2017 and expect to recognize revenue and margin from that product line beginning in the fourth quarter of 2017.

Research and Development Expenses

Research and development expenses consist primarily of engineering and related management and support personnel costs; fees for outside engineering design services which we use from time to time to supplement our internal resources; depreciation expense related to our assets used in product development; prototype production and materials costs, which represent the fabrication and packaging costs for prototype integrated circuits, as well as the cost of supporting components for prototype board development; software licensing and support costs, which represent the annual licensing and support maintenance for engineering design and other software tools; and rent and other overhead costs for our engineering design facility.  Personnel costs include share-based compensation amounts which have been determined based on the grant date fair value of equity-based awards to our employees and then recorded to expense over the vesting period of the award. Condition

 

Our research and development expenses decreasedworking capital increased approximately $0.1$13.3 million or 10%, during the three months ended September 30, 2017 when comparedfrom December 31, 2022 to the same periodMarch 31, 2023.  This increase in 2016.  Thisworking capital is primarily the result of a decrease in share-based compensation expenseour restricted cash balance of approximately $0.2$13.9 million, which is partially offset by an increase in personnelcurrent liabilities from the reclassification of an additional $0.8 million of convertible notes due in February and related costs of approximately $0.1 million. March 2024 from long-term to current liabilities.

 

Our research and development expenses increased approximately $1.2long-term liabilities decreased $0.6 million or 49%, duringfrom December 31, 2022 to March 31, 2023, primarily due to a $0.3 million decrease in the nine months ended September 30, 2017 when compared tofair value of our contingent payment obligations, the same period in 2016.  This is primarily the resultreclassification of an increaseadditional $0.8 million of convertible notes due in costs relatedFebruary and March 2024 from long-term to integrated circuit designcurrent liabilities, and fabricationthe conversion of approximately $0.4 million, an increase in share-based compensation expense of approximately $0.1 million, an increase in personnel and related costs of approximately $0.2 million an increase in software licensing and support costsconvertible notes by the holder, offset by the issuance of approximately $0.1$0.7 million and an increase in outside engineering design services of approximately $0.1 million.new five-year convertible notes.

 

The increases in personnel costsResults of Operations for the three months ended March 31, 2023 and nine month periods is a result2022

Revenue and Cost of staff additions to support the new consumer product line.  The changes in share-based compensation expenseSales

We reported no licensing revenue for the three months ended March 31, 2022.  Licensing revenue was $25.0 million for the three months ended March 31, 2023, resulting from a patent license and nine month periodssettlement agreement entered into in February 2023.  The parties' performance obligations were met in February 2023 and we recognized revenue at that time.  Cost of sales for the three months ended September 30, 2017 is the resultMarch 31, 2023 and 2022 consists of amortization expense attribution related to vesting of share-based awards grantedthe patents covered under license agreements.  Although we anticipate additional revenue to engineering executivesresult in 2023 and other employees in August 2016beyond from our patent enforcement actions, the amount and August 2017. The increases in integrated circuit designtiming is highly unpredictable and fabrication, software licensing and support, and engineering design services are primarily related to development of a Wi-Fi system on chip.there can be no assurance that we will achieve our anticipated results.

 

Selling, General, and Administrative Expenses

Selling, general and administrative expenses consist primarily of executive, director, saleslitigation fees and marketing,expenses, personnel and finance and administrative personnelrelated costs, including share-based compensation, for executive, Board, finance and accounting and technical support personnel for our patent enforcement program, and costs incurred for insurance shareholder relations and outside professional fees for accounting, legal and professional services, including litigation expenses. business consulting services.

 

Our selling, general and administrative expenses decreasedincreased by approximately $0.2$10.2 million, or 5%525.2%, during the three months ended September 30, 2017March 31, 2023 when compared to the same period in 2016.2022.  This is primarily the result of a $0.7an $10.7 million decrease in share-based compensation expense partially offset by an increase of approximately $0.5 million in marketing and advertising costs.

Our selling, general and administrative expenses decreased approximately $4.0 million or 30%, during the nine months ended September 30, 2017 when compared to the same period in 2016.  This is the result of a decrease in litigation fees and expenses of approximately $5.5 million,and is partially offset by ana $0.6 million decrease in share-based compensation.

The increase in marketinglitigation fees and advertising costsexpenses is the result of approximately $0.8 million, an increasecontingent legal fees and expenses recognized in personnel2023 in conjunction with the confidential patent license and related cost of approximately $0.3 million.  

18


settlement agreement reached in February 2023.

 

The decrease in litigation related feesour share-based compensation for the three-month period ended March 31, 2023 is the result of share-based compensation expense attributed to restricted stock units and expenses is primarilynonqualified stock options awarded to executives, key employees and nonemployee directors in 2020 and 2021 being fully recognized as of December 31, 2022.  As of March 31, 2023, we had $0.4 million of total unrecognized compensation cost related to contingent fee arrangements with our litigation firms.  The increases in marketing and advertising costs and the increases in personnel costs are relatedall non-vested share-based compensation awards that is expected to the launch and supportbe recognized over a period of our new consumer product. approximately 0.9 years.

 

Change in Fair Value of Contingent Payment ObligationObligations

We have elected to measure our secured and unsecured contingent payment obligationobligations at fair value which is based on significant unobservable inputs. We estimated the fair value of our secured contingent payment obligationobligations using ana probability-weighted income approach based on the estimated present value of projected future cash outflows using a risk-adjusted discount rate. Increases or decreases in the significant unobservable inputs could result in significant increases or decreases in fair value.

For the nine months  ended September 30, 2017, we recorded a decrease in the fair value of our secured contingent payment obligation of approximately $0.1 million, compared to an increase in the fair value of our secured contingent payment obligation of approximately $3.0 million for nine months ended September 30, 2016.  The Generally, changes in fair value are a result of changes in the estimated timingamounts and amounttiming of projected future cash outflows resulting fromflows due to increases in funded amounts, passage of time, and changes in the probabilities based on the status of the funded actions.

 

Adjusted Net Loss and Adjusted Net Loss Per Share

Adjusted net loss increased by approximately $3.7 million duringFor the three months ended September 30, 2017 when compared toMarch 31, 2023 and 2022, we recorded an aggregate decrease in the same periodfair value of our secured and unsecured contingent payment obligations of approximately $0.3 million and $2.3 million, respectively.  The change in 2016.  The increase in adjusted net loss isfair value for the three months ended March 31, 2023 was primarily the result of the revenuechanges in the three months ended September 30, 2016 which was not recurringestimated amounts and timing of projected future cash flows due to changes in 2017, somewhat offset by increases in marketingprobabilities and advertising costs.   On a per share basis, our adjusted net loss per common share increased by $0.20 per share.   This increase is a resulttime frames based on the status of the increase in our adjusted net loss and a 40% increase in our weighted average common shares outstanding. various patent infringement actions.

 

Adjusted net loss remained the same between the nine months ended September 30, 2017 when compared to the same period in 2016.  On a per share basis, our adjusted net loss per common share decreased by $0.28 per share, or 29%.   This decrease is primarily a result of a 42% increase in our weighted average common shares outstanding. 

19


Reconciliation of Non-GAAP Financial Measures

The following table presents a reconciliation of our net loss to the non-GAAP measure of adjusted net loss for the three and nine months ended September 30, 2017 and 2016, respectively (in thousands):



 

 

 

 

 

 

 

 

 

 

 

 



 

 

 

 

 

 

 

 

 

 

 

 



 

Three Months Ended

 

Nine Months Ended



 

September 30,

 

September 30,



 

2017

 

2016

 

2017

 

2016

Net loss

 

$

(4,380)

 

$

(2,334)

 

$

(12,916)

 

$

(15,838)

Excluded items:

 

 

 

 

 

 

 

 

 

 

 

 

Share-based compensation

 

 

503 

 

 

1,423 

 

 

1,708 

 

 

1,488 

Change in fair value of contingent payment obligation

 

 

38 

 

 

726 

 

 

(129)

 

 

3,033 

 Adjusted net loss

 

$

(3,839)

 

$

(185)

 

$

(11,337)

 

$

(11,317)



 

 

 

 

 

 

 

 

 

 

 

 

The following table presents a reconciliation of our net loss per common share to the non-GAAP measure of adjusted net loss per common share for the three and nine months ended September 30, 2017 and 2016, respectively:



 

 

 

 

 

 

 

 

 

 

 

 



 

 

 

 

 

 

 

 

 

 

 

 



 

Three Months Ended

 

Nine Months Ended



 

September 30,

 

September 30,



 

2017

 

2016

 

2017

 

2016

Basic and diluted net loss per common share

 

$

(0.24)

 

$

(0.18)

 

$

(0.76)

 

$

(1.33)

Excluded items on a per share basis

 

 

0.03 

 

 

0.17 

 

 

0.09 

 

 

0.38 

Adjusted net loss per common share

 

$

(0.21)

 

$

(0.01)

 

$

(0.67)

 

$

(0.95)



 

 

 

 

 

 

 

 

 

 

 

 

Off-Balance Sheet Transactions, Arrangements and Other Relationships

 

As of September 30, 2017,March 31, 2023, we had outstanding warrants to purchase approximately 0.410.3 million shares of our common stock. The estimated grant date fair value of these warrants of approximately $0.8$3.2 million is included in shareholders’ (deficit) equitydeficit in our condensed consolidated balance sheets. The outstanding warrants have ana weighted average exercise price of $2.21$0.75 per share and a weighted average remaining life of approximately 31.9 years.

 

Contractual Obligations

 

There have been no material changes in our contractual obligations as set forth in our Annual Report, except as follows:

In April 2017, we entered into a new lease agreement for our Lake Mary, Florida facility with a lease commencement date of July 1, 2017.  The lease provides for a straight-lined monthly base rental payment of approximately $13,000 through November 2022 with an option for renewal. 

In July 2017, we entered into a new lease agreement for warehouse and assembly space in Jacksonville, Florida.  The lease provides for a straight-lined monthly base rental payment of approximately $2,000 through July 2020 with options for expansion and renewal.

In July 2017, we also amended the lease for our existing Jacksonville, Florida facility to extend the lease expiration date from January 15, 2018 to July 15, 2018.  The lease provides for a straight-lined monthly base rental payment of approximately $28,000 through July 2018.

20


Critical Accounting Policies

 

There have been no changes in critical accounting policies from those stated in our 2022 Annual Report.  We do not expect any newly effective accounting standards to have a material impact on our financial position, results of operations or cash flows when they become effective.

 

ITEMITEM 3. Quantitative and Qualitative Disclosures About Market Risk.

 

For the three and nine months ended September 30, 2017, there were no material changes from the market risk information disclosed under Item 7A of Part II of our Annual Report.  We are exposed to market risk from changes in currency exchange rates that could impact our results of operations and financial position.  We have assets and liabilities denominated in non-functional currencies which are remeasured at each reporting period.  Any gains or losses recognized for changes in currency exchange rates are included in operating expenses in our condensed consolidated statements of comprehensive loss.  We do not consider the market risk from changes in currency exchange rates to be material.Not applicable.

 

ITEMITEM 4. Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures

 

As of September 30, 2017,March 31, 2023, our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our “disclosure controls and procedures,” as defined in Rule 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934, as amended (the “Exchange Act”).  Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that these disclosure controls and procedures were effective as of September 30, 2017.March 31, 2023.  

 

Changes in Internal Control Over Financial Reporting

 

During our quarter ended September 30, 2017, we implemented an inventory module within our existing financial reporting system to support our inventory management, purchase and sales processes.  We also implemented an ecommerce system to support future revenue, receivables and collections.  The implementation of these systems resulted in the addition of reports, interfaces and automated controls as well as manual controls and processes designed to ensure the accuracy of financial and other data.  Therefore, we have modified the design and documentation of internal control processes and procedures to enhance existing internal controls.  These changes were undertaken to support our ecommerce product launch. 

Except for the matters discussed above, thereThere have been no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) under the Exchange Act that occurred during the last fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

 

PARTPART II - OTHER INFORMATION

 

ITEM 1. Legal Proceedings.

 

Reference is made to the section entitled “Legal Proceedings” in Note 1312 to our unaudited condensed consolidated financial statements included in this quarterly report for a discussion of current legal proceedings, which discussion is incorporated herein by reference.

 

ITEM 1A. Risk Factors.

 

There have been no material changes from the risk factors disclosed in Item 1A of Part I of our Annual Report. In addition to the information in this quarterly report, the risk factors disclosed in our Annual Report should be carefully considered in evaluating our business because such factors may have a significant impact on our business, operating results, liquidity and financial condition.

 

We are reliant on component suppliers and contract manufacturers for adequate supply of components for our products, and the failure of our supply chain due to financial problems of suppliers, a shortage of adequate component supply or manufacturing capacity, or other factors that results in an increase in our costs or a delay in our ability to fill customer orders, could have an adverse impact on our business or operating results.

Our growth and ability to meet customer demand for our products depend, in part, on our ability to obtain timely deliveries of parts from our suppliers and contract manufacturers. We may in the future experience a shortage of certain component parts as a result of our own manufacturing issues, manufacturing or capacity issues at our suppliers or contract manufacturers, financial problems of our suppliers, or strong demand in the industry for those parts. During periods of shortages or delays, the price of components may increase, or the components may not be available at all. We may also encounter shortages if we do not accurately anticipate our needs. We may not be able to secure enough components at reasonable prices or of acceptable quality to build new products to meet customer demand. A reduction or interruption in supply, a significant increase in the price of one or more components, or a failure to appropriately adjust our requirements based on our business needs, could adversely impact our revenue and gross margins.

If we fail to properly estimate customer demand for our products, an oversupply of component parts could result in excess or obsolete inventory that could adversely affect our operating results.

Our operating results would be adversely affected if, anticipating greater demand for our products than actually develops, we commit to the purchase of more component parts than we need which is more likely to occur in a period of demand uncertainties such as during the rollout of a new product line like our Milo product line.  In addition, component purchase commitments made by us in order to shorten lead times could also lead to excess and obsolete inventory charges.  If we fail to anticipate customer demand properly, an oversupply of component parts could result in excess or obsolete components that could adversely affect our gross margins and operating results.

If we experience quality issues with our products, our competitive position, business and market opportunity may be impaired.

We produce products that incorporate leading-edge technology, including both hardware and software. Software typically contains bugs that can unexpectedly interfere with expected operations. There can be no assurance that our pre-shipment testing programs will be adequate to detect all defects, either ones in individual products or ones that could affect numerous shipments, which might interfere with customer satisfaction, reduce sales opportunities, or affect gross margins. If we have to replace certain components and provide remediation in response to the discovery of defects or bugs in products that we had shipped, there can be no assurance that such remediation would not have a material impact. An inability to cure a product defect could result in the failure of a product line, damage to our reputation, inventory costs, or

22


product reengineering expenses, any of which could have a material impact on our revenue, margins, and net income.

ITEMITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

OnIn January 31, 2017,2023, we issued 100,000 shares of our common stock to a consultant in paymententered into purchase agreements with accredited investors which provided for executive advisory services valued at approximately $0.1 million.  These shares were issued pursuant to the exemption from registration provided by Section 4(2) of the Securities Act of 1933, as amended, as the vendor is a sophisticated investor, with such knowledge and experience in financial and business matters that it is capable of evaluating the merits and risks of the investment.

On February 10, 2017, we issued 200,000 shares of our common stock to a consultant in payment for consulting services valued at $0.3 million.   These shares were issued pursuant to the exemption from registration provided by Section 4(2) of the Securities Act of 1933, as amended, as the vendor is a sophisticated investor, with such knowledge and experience in financial and business matters that it is capable of evaluating the merits and risks of the investment.

On February 21, 2017, we consummated the sale of 80,510convertible notes with an aggregate face value of $0.7 million.  The outstanding principal and interest accrued on the notes are convertible at any time and from time to time by the holders into shares of our common stock at a fixed conversion price of $2.11$0.16 per shareshare.  Any unconverted, outstanding principal amount is payable in cash on the five-year anniversary of the issuance date of the notes.  The shares underlying the notes, as well as shares reserved for future in-kind interest payments on the notes, were registered on a private placement transaction for grossregistration statement that was declared effective on May 11, 2023 (File No. 333-271351).

In January 2023, we received aggregate proceeds of approximately $0.2 million.  The$0.14 million from the sale of common stock to accredited investors at a price of $0.16 per share.  The shares sold were issued pursuant to the exemptionexempt from registration provided byunder Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506 of Regulation D thereunder, as the investor iswere registered for resale on a sophisticated investor, with such knowledge and experience in financial and business mattersregistration statement that it is capable of evaluating the merits and risks of the investment. 

was declared effective on May 11, 2023 (File No. 333-271351).  The proceeds from our unregistered sales of equity securities are beingwere used for general working capital and general corporate purposes.

 

ITEMITEM 3. Defaults Upon Senior Securities.

 

None.

 

ITEMITEM 4. Mine Safety Disclosures.

 

Not applicable.

 

23


ITEMITEM 5. Other Information.

 

On November 14, 2017, we issued a press release announcingMay 12, 2023, Mr. Frank Newman resigned from our financial conditionBoard of Directors, and results offrom the Audit Committee on which he served, for personal reasons.  Mr. Newman's resignation was not due to any disagreement with us or any matter relating to our operations, for the three and nine months ended September 30, 2017.  The earnings press release is attached hereto as Exhibit 99.1.policies or practices (financial or otherwise). 

 

The foregoing information including the exhibit related thereto, is furnished in response to Item 2.025.02 of Form 8-K and shall not be deemed “filed”"filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any disclosure document of the Registrant, except as shall be expressly set forth by specific reference in such document.

 

IT

EMITEM 6. Exhibits.

 

*Filed herewith

** Furnished herewith

 

SIGNATURESSIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

ParkerVision, Inc.

Registrant

November 14, 2017May 15, 2023

By:  

/s/Jeffrey L. Parker

Jeffrey L. Parker

Chairman and Chief Executive Officer

(Principal Executive Officer)

November 14, 2017

May 15, 2023

By:  

/s/Cynthia L. PoehlmanFrench

Cynthia L. PoehlmanFrench

Chief Financial Officer

ChiefFinancialOfficer

(Principal Financial Officer and Principal

Accounting Officer)

25


EXHIBIT INDEX

31.1 

Section 302 Certification of Jeffrey L. Parker, CEO

31.2 

Section 302 Certification of Cynthia L. Poehlman, CFO

32.1 

Section 906 Certification

99.1 

Earnings Press Release

101.INS

XBRL Instance Document

101.SCH

XBRL Taxonomy Extension Schema

101.CAL

XBRL Taxonomy Extension Calculation Linkbase

101.DEF

XBRL Taxonomy Extension Definition Linkbase

101.LAB

XBRL Taxonomy Extension Label Linkbase

101.PRE

XBRL Taxonomy Extension Presentation Linkbase

 

 

 

26